Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Kreios Space to fly VLEO demonstration in NanoAvionics bus

SAN FRANCISCO – Spanish startup Kreios Space announced plans Aug. 4 to conduct the first very low Earth orbit (VLEO) demonstration of its air-breathing electric propulsion (ABEP) in a Kongsberg NanoAvionics microsatellite bus.

“Partnering with NanoAvionics in our first in-orbit flight provides us with a satellite bus and market-leading experience necessary to allow us to test our new technology in confidence,” Kreios CEO Adrián Senar said in a statement.

Senar declined to comment on the timing of the flight. Kreios’ website says the “the first-ever ABEP-based VLEO mission,” will occur in 2027 with a second flight in 2028.

AI, Quantum Computing, Nanotech Convergence Reshapes Innovation

Artificial intelligence, quantum computing and nanotechnology are converging to reshape innovation — and organizations that understand how to harness them could gain a competitive edge.

That’s according to Chuck Brooks, president of Brooks Consulting International and one of Executive Mosaic’s GovCon Experts, in a recent piece exploring how the technologies are transforming research and development while accelerating advances in healthcare, cybersecurity, defense and other industries.

Brooks highlights AI’s role in accelerating R&D, nanotechnology’s potential in wearables and sensors, and quantum computing’s ability to solve complex problems beyond the reach of classical computers.

AI redesign helps enzymes evolve beyond natural limits

Researchers showed that AI-redesigned botulinum neurotoxin proteases provided more stable starting points for directed evolution, allowing enzymes to access beneficial mutations that were poorly tolerated in wild-type backgrounds. In BoNT/E models, the approach improved activity, evolvability, and specificity, including an ataxin-2-targeting variant with markedly reduced cleavage of the native SNAP25 substrate.

Broth Optical DensityBased Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and TimeKill

Phage therapy is the use of bacterial viruses, or bacteriophages, as antibacterial agents. It has been in use for over 100 years and is becoming increasingly common clinically. The first steps of phage therapy include identification of bacteria to be targeted and then obtaining phages with appropriate host ranges. This is followed by various approaches to in vitro phage characterization. Increasingly common for phage phenotypic characterization is the use of kinetic microtiter plate readers. They can both decrease workloads and increase throughput, especially relative to analyses that require plating on agar-based media. These colorimetric/turbidimetric/optical density approaches primarily assess phage-induced culture-wide bacterial lysis, in the shorter term, or instead the phage potential to suppress phage-resistance evolution over longer time frames. Considered here are methods relevant to phage characterization especially for phage-therapy purposes. Discussed are turbidity-reduction assays, determinations of phage antibacterial virulence, and related time-kill curve analysis. All are or can be optical density-based approaches to assessing phage-based bacterial reduction. Emphasis is placed on consideration of the utilities, limitations, and intersections of these similar methods. Emphasized is that the start of “Deviation”—where phage-treated culture turbidity diverges from phage-free controls—may represent a superior endpoint for such optical density-based bacterial-reduction protocols.